Registrational Phase III AMPLIFY trial: Target number of participants achieved
Sydney, Australia 10 March 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Phase III AMPLIFY trial (NCT06970847)1 has now consented in excess of the planned number of participants following strong…